TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11786571
Drug: Aggressive nonmyeloablative
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive nonmyeloablative chemotherapy
Study: 2575981
Drug: epanolol 200mg
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol 200mg daily
Study: 2575981
Drug: metoprolol 100mg
Normalized name: HCTZ 25/METOPROLOL 100MG TAB
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoprolol 100mg twice a day
Study: 2575981
Drug: nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine retard 20mg twice a day
Study: 25689244
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, then 75 mg/day)
Study: 20538132
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of furosemide (mean dose 162 ± 48 mg/24 hours)
Study: 20538132
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of furosemide (mean dose 162 ± 52 mg/24 hours)
Study: 17009113
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg/kg) with midazolam (0.05 mg/kg)
Study: 17009113
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg/kg) with midazolam (0.05 mg/kg)
Study: 17009113
Drug: Tramadol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (2 mg/kg) with midazolam (0.05 mg/kg)
Study: 12699522
Drug: Initial diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial diabetes training for the emergency team and standardized protocol for prehospital emergency therapy of severe hypoglycaemia (SH)
Study: 12699522
Drug: Education of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education of insulin-treated patients about their diabetes
Study: 12699522
Drug: Mandatory additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory additional glucose infusions and hospitalization for sulfonylurea-induced SH
Study: 8928243
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg daily for 24 months
Study: 6430439
Drug: Determination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determination of renal beta 2 microglobulin excretion
Study: 6430439
Drug: Immunofluorescence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunofluorescence of antibody coated bacteria
Study: 6430439
Drug: Scintiphotography with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scintiphotography with 67Ga and determination of renal beta 2 microglobulin excretion
Study: 6430439
Drug: Excretion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excretion of beta 2 microglobulin and uptake of 67Ga in patients with lower urinary tract infections
Study: 31099333
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day magnesium oxide
Study: 27067676
Drug: Eight weekly
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight weekly one hour meditation‐focused mind/body classes teaching concentration and insight meditation skills along with mind/body exercises.
Study: 27067676
Drug: Eight weekly
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight weekly one hour meditation‐focused mind/body classes.
Study: 19909984
Drug: De Vega
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De Vega + pericardial patch augmentation
Study: 19909984
Drug: Ring annuloplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ring annuloplasty + pericardial patch augmentation
Study: 1975333
Drug: M37 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M37 vaccine (1 x 10(4) pfu)
Study: 1975333
Drug: Quadrivalent rotavirus
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent rotavirus vaccine (1 x 10(4) pfu each of serotype 3 RRV and human rotavirus‐RRV reassortants of serotypes 1, 2, and 4)
Study: 1975333
Drug: Balanced quadrivalent
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced quadrivalent vaccine (1 x 10(4) pfu of serotype 1 and 3 components but 5 x 10(4) pfu of serotype 2 and 4 components)
Study: 6791212
Drug: 0.50 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 ml/kg alcohol
Study: 6791212
Drug: 1.0 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml/kg alcohol
Study: 6791212
Drug: 0.025 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 ml/kg alcohol
Study: 26721142
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with acupoint embedding therapy
Study: 21169640
Drug: Phenobarbital (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (40 mg/kg)
Study: 2959426
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals)
Study: 2959426
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 to 10 mg b.i.d.)
Study: 29635693
Drug: CO2 fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 fractional laser treatment (one treatment each month) with topical 0.1% tacrolimus cream
Study: 29635693
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% tacrolimus cream
Study: 26541905
Drug: Rapid-onset antiplatelet
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-onset antiplatelet therapy (prasugrel or glycoprotein IIb-IIIa) in the prehospital setting
Study: 25070482
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral product of pioglitazone hydrochloride with increased hydroxypropyl cellulose (HPC)
Study: 25070482
Drug: Reference listed
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference listed drug (RLD) pioglitazone hydrochloride
Study: 20670726
Drug: Verapamil SR-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil SR-based treatment
Study: 20670726
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment strategies (Verapamil SR and Atenolol)
Study: 12744767
Drug: Warming therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming therapy using a Warm Up device (n = 8)
Study: 11171790
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of vitamin C
Study: 11171790
Drug: Sequential infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential infusions of dobutamine (Dob, Dob-2) without vitamin C
Study: 9394695
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with metronidazole for E. histolytica
Study: 3445589
Drug: Live combined
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live combined mumps-measles vaccine (MMV)
Study: 9106373
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) with ERT
Study: 9106373
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) without ERT
Study: 21226937
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive therapy (CT) while tapering antidepressants (AD)
Study: 21226937
Drug: Maintenance antidepressants
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antidepressants (AD)
Study: 21226937
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brief cognitive therapy (CT) with maintenance antidepressants (AD)
Study: 12739706
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily (o.d.)
Study: 12739706
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg twice daily (b.i.d.)
Study: 10561627
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 microg at 4-hour intervals for a maximum of 6 doses)
Study: 10561627
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter plus oxytocin (maximum dose of 36 mU/min)
Study: 8901793
Drug: Follow-up for
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up for calcium tablet group
Study: 1667474
Drug: Customary oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary oral hygiene procedures
Study: 6351894
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir ointment, applied five times a day for 5 days
Study: 22845494
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) tapentadol 50 mg
Study: 22845494
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) tapentadol 75 mg
Study: 22845494
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) tapentadol (unspecified dosage)
Study: 17533178
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (50 microg per nostril per day) for 40 days
Study: 17533178
Drug: Topical intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intranasal steroid treatment on alternate days for the first 2 weeks per month (group A1)
Study: 17533178
Drug: Continued daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued daily mometasone treatment for the first 2 weeks per month (group A2)
Study: 17533178
Drug: Mometasone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone treatment
Study: 15621710
Drug: Vegetal formulation
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetal formulation of superoxide dismutase (SOD)
Study: 7530473
Drug: L-NMMA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (2 mumol min-1) with bradykinin (100 pmol min-1)
Study: 7530473
Drug: L-NMMA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (4 mumol min-1) with bradykinin (100 pmol min-1)
Study: 7530473
Drug: L-NMMA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (2 mumol min-1) with substance P (1 pmol min-1)
Study: 7530473
Drug: L-NMMA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (4 mumol min-1) with substance P (1 pmol min-1)
Study: 3292363
Drug: Azathioprine at
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine at a dose of 2 mg per kg
Study: 3292363
Drug: Conventional combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional combination regimen of azathioprine (1 mg per kg) with prednisolone
Study: 31682162
Drug: Acumapimod 75
Normalized name: Acumapimod
DrugBank: Acumapimod (DB15448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acumapimod 75 mg repeated single-dose on Days 1 and 6
Study: 31682162
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 40 mg (10 days)
Study: 31682162
Drug: Acumapimod 20
Normalized name: Acumapimod
DrugBank: Acumapimod (DB15448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acumapimod 20 mg single-dose
Study: 28903510
Drug: RAL (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL (400 mg twice daily)
Study: 21240871
Drug: ARB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB group (valsartan 40-80 mg daily for 6 months)
Study: 19406981
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg plus isoniazid placebo
Study: 19406981
Drug: Isoniazid 300
Normalized name: isoniazid 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 300 mg plus moxifloxacin placebo
Study: 10829320
Drug: Preoperative visualization
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative visualization therapy (Group A)
Study: 10829320
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative therapy (Group B)
Study: 8891847
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (interferon alone and combined therapy)
Study: 1381022
Drug: Isradipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 1.25 mg twice daily (b.i.d.)
Study: 28089180
Drug: PL2200 (modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL2200 (modified-release lipid-based aspirin, 325 mg)
Study: 28089180
Drug: Delayed-release enteric-coated
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed-release enteric-coated (EC) aspirin (325 mg)
Study: 21199966
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (BLT) for 3 weeks, 1-hour early-morning exposure to pale blue light at approximately 7500 lux
Study: 21199966
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (BLT)
Study: 19595483
Drug: Lansoprazole orally
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole orally disintegrating tablets (30mg for 3 days)
Study: 19595483
Drug: Lansoprazole capsules
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole capsules (30mg for 3 days)
Study: 19595483
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to pay for orally disintegrating tablets
Study: 26170014
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron intervention
Study: 17999080
Drug: 200‐mg/day doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg/day doxycycline for 4‐6 weeks
Study: 12765924
Drug: Aerochamber (AC)
Normalized name: AEROCHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerochamber (AC) with 200 micro g budesonide twice daily
Study: 12765924
Drug: Nebuchamber (NC)
Normalized name: codeine phosphate / pseudoephedrine hydrochloride / triprolidine hydrochloride Oral Solution [Poly Hist NC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuchamber (NC) with 200 micro g budesonide twice daily
Study: 9124243
Drug: Topical carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical carteolol hydrochloride 1%
Study: 8267038
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus low-dose aspirin (n = 12)
Study: 8267038
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (n = 22)
Study: 31397133
Drug: Ultrasound-guided intrathecal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided intrathecal injection (control group)
Study: 27862108
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy (CBT4BN)
Study: 27862108
Drug: Traditional face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional face-to-face group cognitive-behavioral therapy (CBTF2F)
Study: 19328598
Drug: Practidose individualised
Normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practidose individualised dispensing and dosing pillbox system
Study: 16603337
Drug: Parent-implemented Reciprocal
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-implemented Reciprocal Imitation Training (RIT), implemented twice a week for 10 weeks.
Study: 16603337
Drug: Generalization assessed
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalization assessed in families' homes at the end of treatment and a 1-month follow-up.
Study: 16827430
Drug: Hypervolemic hypertensive
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypervolemic hypertensive hemodilution (3H-therapy)
Study: 16827430
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no 3H-therapy)
Study: 12662378
Drug: Lafutidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine (20 mg twice daily)
Study: 12662378
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg twice daily)
Study: 1706207
Drug: Alkylating agents
Normalized name: ALKYLATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agents or intensive chemotherapy
Study: 6124236
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (desensitization followed by Masters and Johnson)
Study: 31771991
Drug: Mobile low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mobile low-dose CT screening unit
Study: 25741580
Drug: Probiotic-containing lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-containing lozenges
Study: 23446957
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg
Study: 18037544
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg vaccine
Study: 18037544
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg vaccine
Study: 18037544
Drug: 2.5 microg
Normalized name: Digoxin 62.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 microg vaccine
Study: 18037544
Drug: Four low
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four low doses of 2.5 microg
Study: 18037544
Drug: Four low
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four low doses of 5 microg
Study: 17172187
Drug: Rifaximin 200
Normalized name: rifAXIMin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 200 (2 cp bid for ten days in a month) followed by Bifidobacterium longum W11 (one granulated suspension for 6 days on alternate weeks)
Study: 9206199
Drug: Anti-lipid A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-lipid A of LPS antibody (anti-LPS treatment group)
Study: 1728077
Drug: Ranitidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (100 mg intravenously every 12 hours for 72 hours)
Study: 6383045
Drug: Ritodrine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine, 120 mg daily (oral)
Study: 6383045
Drug: Terbutaline, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline, 30 mg daily (oral)
Study: 6383045
Drug: Terbutaline (oral)
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline (oral)
Study: 6383045
Drug: Ritodrine (oral)
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine (oral)
Study: 6383045
Drug: Ritodrine (intravenous)
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine (intravenous)
Study: 6383045
Drug: Terbutaline (intravenous)
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline (intravenous)
Study: 26930488
Drug: Therapist-Assisted Internet-delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-Assisted Internet-delivered Cognitive Behavior Therapy (TA-ICBT)
Study: 11181239
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy at a mean flow rate of 1.3 +/- 0.4 l/min
Study: 11181239
Drug: Air administered
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air administered at the same flow rate
Study: 7910230
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with PSK (protein‐bound polysaccharide)
Study: 7910230
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (mitomycin plus oral fluorouracil)
Study: 2967433
Drug: Aspirin-dipyridamole combination
Normalized name: aspirin / dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-dipyridamole combination (330 mg-75 mg) given three times daily, with intravenous dipyridamole at 10 mg per hour for 24 hours before PTCA.
Study: 2967433
Drug: Aspirin-dipyridamole combination
Normalized name: aspirin / dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-dipyridamole combination (active drug)
Study: 31959416
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and heparin treatment with aggressive fluid resuscitation
Study: 26220439
Drug: Plum-blossom needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plum-blossom needle therapy
Study: 23897332
Drug: Lidocaine in
Normalized name: lidocaine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine in infiltration solution
Study: 23897332
Drug: Control (infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (infiltration solution without lidocaine)
Study: 14620619
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy plus bovine lactoferrin (group A)
Study: 14620619
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (group B)